Shantha Biotechnics awarded large vaccine contracts by United Nations agency
Shantha awarded 2010-2012 contracts for pentavalent vaccine SHAN5™ (DTP, HiB, Hep.B)
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Shantha Biotechnics was awarded contracts by a United Nations agency for supplies of pentavalent vaccine SHAN5™ (combination vaccine of diphtheria, pertussis, tetanus, Haemophilus influenza B, and Hepatitis B). The contracts, worth $340 million, cover the period 2010-2012.
Sanofi Pasteur, through its existing and new contracts, now provides a full range of vaccines used within the Expanded Program on Immunization (EPI) of the World Health Organization (WHO).
Commenting on the contracts, Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur, said: “These awarded contracts underline Shantha Biotechnics’ high expertise and the quality of their state-of-the-art manufacturing facilities. While Shantha Biotechnics is joining the sanofi-aventis Group, those contracts perfectly illustrate our ambition to provide the best vaccines at affordable prices to many people around the world.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.